Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Olaptesed pegol - TME Pharma

Next Previous
Drug Profile

Olaptesed pegol - TME Pharma

Alternative Names: Anti-CXCL12/SDF-1 Spiegelmer®; NOX-A12

Latest Information Update: 29 Jun 2023

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator NOXXON Pharma AG
  • Developer TME Pharma
  • Class Antineoplastics; Eye disorder therapies; Oligonucleotides; Polyethylene glycols; Small molecules
  • Mechanism of Action Chemokine CXCL12 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Glioblastoma; Glioma
  • New Molecular Entity Yes
  • Available For Licensing Yes - Cancer

Highest Development Phases

  • Phase II Chronic lymphocytic leukaemia; Multiple myeloma
  • Phase I/II Colorectal cancer; Glioblastoma; Pancreatic cancer
  • Discontinued Diabetic retinopathy

Most Recent Events

  • 28 Jun 2023 Updated efficacy data from the phase I/II GLORIA trial in Glioblastoma released by TME Pharma
  • 15 Jun 2023 US FDA approves the phase II OPTIMUS trial protocol for Olaptesed pegol in Pancreatic cancer (Combination therapy, Second-line therapy or greater) in USA
  • 15 Jun 2023 TME Pharma plans the phase II OPTIMUS trial for Pancreatic cancer (Combination therapy, Second-line therapy or greater) in France, Spain and USA (NCT04901741) (EudraCT2021-001963-25)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top